Physician profile
Javier Calderon
NPI 1538141718
$2,681.69
in general payments reported to CMS, 2019-2025
13 companies · $671 in 2025
The $671 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $270 · 2021: $213 · 2022: $234 · 2023: $401 · 2024: $382 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.74 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $535.65 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $429.23 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Shionogi INC | $367.70 | 2022-2025 | Fetroja |
| Abbvie INC. | $358.83 | 2021-2025 | Dalvance |
| Insmed, INC. | $336.61 | 2019-2024 | Arikayce |
| Melinta Therapeutics, LLC | $232.98 | 2021-2025 | Rezzayo, Kimyrsa |
| Allergan, INC. | $160.55 | 2019-2020 | |
| Novo Nordisk INC | $89.12 | 2022 | |
| La Jolla Pharmaceutical Company | $75.96 | 2021-2024 | Xerava, Xacduro |
| Viiv Healthcare Company | $43.18 | 2019-2025 | Dovato |
| Aimmune Therapeutics, INC. | $24.12 | 2024 | |
| Horizon Therapeutics Plc | $15.68 | 2022 | |
| Glaxosmithkline, LLC. | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Calderon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.